The increased number of regulatory filings for cell and gene therapies requires reevaluation of bioassay methods because of their complexity.
Benjamin Ziehr
Advertisement
Benjamin Ziehr, PhD, is senior group leader at PPD Laboratories’ GMP cell lab.
Articles by Benjamin Ziehr
Advertisement
Latest Updated Articles
Development Strategies for Cell and Gene Therapy MethodsPublished: June 1st 2021 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
2
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
